Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
04 Avril 2024 - 1:30PM
Business Wire
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a
clinical-stage biotechnology company pioneering mRNA cell therapy
for autoimmune diseases, today announced that its management
expects to participate in a fireside chat at the 23rd Annual
Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at
3:00 p.m. ET.
A live webcast of the fireside chat is expected to be accessible
in the Events section of the Company’s website at
www.cartesiantherapeutics.com, where an archived replay of the
event will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering
mRNA cell therapies for the treatment of autoimmune diseases. The
Company’s lead asset, Descartes-08, is a potential first-in-class
mRNA CAR-T in Phase 2b clinical development for patients with
generalized myasthenia gravis. Additional Phase 2 studies are
planned in systemic lupus erythematosus under an allowed IND, as
well as basket trials in additional autoimmune indications. The
Company’s clinical-stage pipeline also includes Descartes-15, a
next-generation, autologous anti-BCMA mRNA CAR-T. For more
information, please visit www.cartesiantherapeutics.com or follow
the Company on LinkedIn or X, formerly known as Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240404214878/en/
Investor Relations: Melissa Forst Argot Partners
cartesian@argotpartners.com Media: David Rosen Argot Partners
cartesian@argotpartners.com
Cartesian Therapeutics (NASDAQ:RNAC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Cartesian Therapeutics (NASDAQ:RNAC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
